Q4 2025 · 13F-HR
Enavate Sciences GP, LLCholdings as filed
Filed 2026-02-17 · accession 0001953107-26-000003
$506.8M
Reported value
7
Positions
2025-12-31
Period end
The Brief · Enavate Sciences GP, LLC · Q4 2025
AI · grounded in 13F
Enavate Sciences GP, LLC reduced its position in CAMP by 19.81%. The fund accumulated more shares of ZBIO, increasing its holding by 4.20%. Total assets under management for the period ended December 31, 2025, stood at $506.78M across 7 positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 98937L105 | ZBIO | ZENAS BIOPHARMA INC | $142.3M | 28.1% | 3,919,159 | Common | SOLE |
| 45257U108 | IMNM | IMMUNOME INC | $102.4M | 20.2% | 4,768,583 | Common | SOLE |
| 829401108 | SION | SIONNA THERAPEUTICS INC | $101.9M | 20.1% | 2,478,030 | Common | SOLE |
| 91678A107 | UPB | UPSTREAM BIO INC | $66.8M | 13.2% | 2,459,703 | Common | SOLE |
| 20454B104 | CMPX | COMPASS THERAPEUTICS INC | $41.8M | 8.25% | 7,788,150 | Common | SOLE |
| 107924102 | BBOT | BRIDGEBIO ONCOLOGY THERAPEUT | $32.9M | 6.49% | 2,626,946 | Common | SOLE |
| 13463J101 | CAMP | CAMP4 THERAPEUTICS CORP | $18.6M | 3.67% | 3,035,825 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.